AbbVie's Shares Dip as Trading Volume Falls to 107th in U.S. Rankings Amid Patent Battles and Oncology Hopes

On September 16, 2025, AbbVie (ABBV) closed with a 0.62% decline, trading with a daily volume of $920 million, ranking 107th among U.S. stocks by liquidity. The biopharmaceutical giant's share price movement appears tied to its strategic positioning in the healthcare sector amid evolving market dynamics.

Recent developments highlight AbbVie's ongoing efforts to strengthen its patent portfolio for Humira, the blockbuster rheumatoid arthritis drug facing generic competition. The company has secured extended exclusivity in key markets through litigation victories, which analysts suggest could delay revenue erosion by 12-18 months. This defensive strategy contrasts with peers who have opted for accelerated pipeline transitions.

Regulatory updates indicate the FDA is reviewing AbbVie's application for a new oncology therapy, with a decision expected by year-end. While the outcome remains uncertain, the drug's potential to generate $2 billion in annual revenue has been factored into current valuation metrics. Market participants are closely monitoring clinical trial data transparency in upcoming investor calls.

To run this back-test accurately I need to know the exact stock universe we should work with. The phrase “top 500 stocks by daily trading volume” can be interpreted in a few different ways: 1. Dynamic universe – every trading day we rank all U.S. listed common stocks by that day’s share volume and buy the top 500. • This is truest to your wording, but it requires pulling volume data for thousands of tickers each day. • It’s doable, but the data load is large and the run time will be noticeably longer. 2. Static universe – treat the S&P 500 constituents as a reasonable proxy (they are almost always among the most actively traded) and simply buy them equally every day. • Much lighter and quicker to run. • Data readily available. 3. Index/ETF proxy – use an ETF such as RSP (equal-weight S&P 500) or SPY (cap-weight S&P 500) as a single-ticker stand-in for the portfolio’s return. • Fastest approach, but obviously an approximation. Please let me know which option (or another one) fits your objectives. If you choose 1 or 2, also confirm: • Execution price: use each day’s close to buy and next day’s close to sell? • Weighting: equal-weight across the selected stocks? As soon as I have these details I can launch the back-test.